title: Toward optimizing pomalidomide therapy in MM patients.
abstract: In this issue of Blood, Sehgal et al report on the clinical and pharmacodynamics analysis of pomalidomide dosing strategies in multiple myeloma (MM) and their impact on immune activation and cereblon targets. The particular novelty of this study lies in the direct correlation of immune effects triggered by pomalidomide with clinical responses in MM patients. Results of this study will stimulate many additional studies.
authors.affiliation: UNIVERSITY OF HEIDELBERG.
authors.forename: Klaus
authors.initials: K
authors.lastname: Podar
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D013792:Thalidomide / Q000031:analogs & derivatives*
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide